Figure 3.

Relative CDCA5 expression in renal cancer cell lines and tissues with its survival significance. (A) Protein expression of CDCA5 in renal cancer cell lines examined using western blot analysis. (B) Relative mRNA expression of CDCA5 in 21 pairs of ccRCC tissues and adjacent tissues examined using reverse transcription-quantitative PCR. (C) Representative tissue microarray stained for CDCA5 in 137 patients with ccRCC. The immunoreactivity of CDCA5 expression in ccRCC and normal tissues was analyzed based on different cancer stages. Upper panels: Magnification, ×4; scale bar, 500 µm; lower panels: Magnification ×40; scale bar, 50 µm. (D) IHC score of CDCA5 expression was significantly higher in ccRCC tissues with an advanced T stage, positive lymphatic metastasis, distant metastasis, higher TNM stage, and elevated pathological grade. The IHC score was quantified according to the integrated optical density per filed. (E) Kaplan-Meier survival analysis indicated a poor OS and DFS of patients with ccRCC with a high CDCA5 expression. (F) Forest plot of hazard ratios for DFS and OS. Multivariate cox regression model of prognostic factors is displayed with 95% CI values. ^*P<0.05, ^**P<0.01, ^***P<0.001 and ^****P<0.0001 vs. paratumor tissue. CDCA5, cell division cycle-associated 5; ccRCC, clear cell renal cell carcinoma; IHC, immunohistochemistry; DFS, disease-free survival; OS, overall survival.